Teladoc Health (TDOC) dropped 5% after reporting a wider Q3 loss. Rafael Holdings (RFL) slumped by 78% after saying that the late-stage trial of CPI-613 combined with modified Folfirinox in patients with metastatic adenocarcinoma of the pancreas did not meet its primary endpoint of overall survival. In other company news, Merck (MRK) reported higher fiscal Q3 results and raised its full-year financial guidance.